Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Blank

Showing results (131-140 of 317) with videos related to

Pageof 32
Sort By:
European Urology Open Science|January 13, 2022
Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data AssessmentAafke Meerveld-Eggink, Niels Graafland, Sofie Wilgenhof, et al.
The Lancet. Oncology|February 19, 2013
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 studyPaolo A Ascierto, Dirk Schadendorf, Carola Berking, et al.
ESMO Open|February 2, 2018
Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to managementMarnix H Geukes Foppen, Elisa A Rozeman, Sandra van Wilpe, et al.
Cancer Chemotherapy and Pharmacology|March 22, 2023
Exposure-response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patientsStefanie L Groenland, J M Janssen, C M Nijenhuis, et al.
Immuno-Oncology Technology|August 26, 2024
Integrated noninvasive diagnostics for prediction of survival in immunotherapyM Yeghaian, Z Bodalal, T M Tareco Bucho, et al.
Science Translational Medicine|April 27, 2022
Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumorsPaulien Kaptein, Celia Jacoberger-Foissac, Petros Dimitriadis, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 21, 2021
Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell responseAnastasia Gangaev, Elisa A Rozeman, Maartje W Rohaan, et al.
The British Journal of Surgery|March 19, 2019
Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanomaB Schermers, V Franke, E A Rozeman, et al.
EMBO Molecular Medicine|June 25, 2015
Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenograftsKristel Kemper, Oscar Krijgsman, Paulien Cornelissen-Steijger, et al.
Cancer Immunology Research|February 8, 2023
Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic CellsEsmée P Hoefsmit, Paula T van Royen, Disha Rao, et al.
Pageof 32

Showing results (131-140 of 317) with videos related to

Sort By:
Pageof 32
European Urology Open Science|January 13, 2022
Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data AssessmentAafke Meerveld-Eggink, Niels Graafland, Sofie Wilgenhof, et al.
The Lancet. Oncology|February 19, 2013
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 studyPaolo A Ascierto, Dirk Schadendorf, Carola Berking, et al.
ESMO Open|February 2, 2018
Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to managementMarnix H Geukes Foppen, Elisa A Rozeman, Sandra van Wilpe, et al.
Cancer Chemotherapy and Pharmacology|March 22, 2023
Exposure-response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patientsStefanie L Groenland, J M Janssen, C M Nijenhuis, et al.
Immuno-Oncology Technology|August 26, 2024
Integrated noninvasive diagnostics for prediction of survival in immunotherapyM Yeghaian, Z Bodalal, T M Tareco Bucho, et al.
Science Translational Medicine|April 27, 2022
Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumorsPaulien Kaptein, Celia Jacoberger-Foissac, Petros Dimitriadis, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 21, 2021
Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell responseAnastasia Gangaev, Elisa A Rozeman, Maartje W Rohaan, et al.
The British Journal of Surgery|March 19, 2019
Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanomaB Schermers, V Franke, E A Rozeman, et al.
EMBO Molecular Medicine|June 25, 2015
Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenograftsKristel Kemper, Oscar Krijgsman, Paulien Cornelissen-Steijger, et al.
Cancer Immunology Research|February 8, 2023
Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic CellsEsmée P Hoefsmit, Paula T van Royen, Disha Rao, et al.
Pageof 32